All pharmaceutical drugs (PDs) have Adverse drug reactions (ADRs) associated with their use in some individuals. ADRs are a leading cause of morbidity and mortality in those using (PDs). It is well known that the number and severity of ADRs associated with the use of PDs are elevated by a number of parameters including age, gender, genetic makeup, polypharmacy, exposure to organic solvents, alcohol, tobacco or recreational drug use, diet, chronic inflammation, preexisting disease and ongoing emotional stress. All the parameters responsible for ADRs also increase oxidative stress (OS) as reflected by the Oxidative Stress Index (OSI). The OSI is hypothesized here to predict the likelihood and severity of ADRs.
I. INTRODUCTION
All pharmaceutical drugs (PDs) have Adverse drug reactions (ADRs) associated with their use and ADRs are a leading cause of morbidity and mortality in those using PDs [Kramer 1981; Alomar, 2014 and the references contained therein]. It is also known that the number and severity of ADRs associated with the use of these medications are elevated by a number of parameters which include include age, gender, genetic makeup, polypharmacy, exposure to organic solvents, alcohol, tobacco or recreational drug use, diet, chronic inflammation, preexisting disease and ongoing emotional stress exposures [Alomar, 2014; Lauschke and Ingelman-Sundberg, 2016; Alhawassi, et al., 2014; Gochfeld, 2017; Mendrick, et al., 2017; Kaufmann, et al., 2015; Sushko. et al., 2012; Grzybowski, et al., 2015; Kramer, 1981] .
All the parameters associated with ADRs are also causative of increased levels of oxidative stress (OS). Total (OS) is associated, in a dose response relationship, with increased likelihood of disease onset and severity of disease [Zeliger, 2016] . It has recently been shown that the oxidative stress index (OSI), based upon responses to a detailed questionnaire that addresses all aspects of a person's OS level, is a predictor of both level of OS and likelihood of disease onset [Zeliger, 2019] . It is proposed here that the likelihood of ADR onset following the start of treatment with a pharmaceutical can be predicted using the OSI. these are included here. The applicability of the OS to predicting disease onset is based upon a literature review of published studies of the causes of OS and the mechanistic relationships between OS and disease onset [Zeliger, 2016] . The OSI is obtained via the use of a questionnaire that probes genetics (family history, age, illnesses and conditions, clinical test results, environmental exposures, lifestyle, medications regularly taken, psychological stress, disease status and chronic symptoms [Zeliger, 2019] .
II. METHODS

Causes of
III. RESULTS AND DISCUSSION
A. Oxidative Stress and Disease Prediction
Elevated oxidative stress is well known to be a direct cause of non-communicable environmental diseases in all body systems as well as an indirect cause of infectious disease via undermining of the immune system. Total OS is increased in a dose response relationship no matter what the cause and total OS can come from any one or multiples of the parameters shown in Table 1 [Zeliger, 2016] . Serum malondialdehyde, the biomarker most often used to measure OS, though a valuable indicator of OS that is stable in serum and easily analyzed for, can vary widely depending upon what a person ate, pollutants he or she may have been exposed to, medications being used, state of emotional status and other OS elevating parameters prevalent when serum is drawn. These variables can cause serum MDA levels to vary by as much as 19 percent over a six day period [Nielsen, et al., 1997 ]. The Oxidative Stress Predicting and Reducing Adverse Drug Reactions (ADRs) Harold I. Zeliger Index (OSI), which is described below, eliminates the uncertainties associated with OS measurement.
B. Adverse Drug Reactions
All pharmaceuticals cause ADRs and produce symptoms that vary from mild to severe to life threatening. The most common symptoms of ADRs are shown in Table 2 [Kramer, 1981] . More severe ADRs include Type 2 diabetes, numerous cancers, cardiovascular diseases, neurological diseases, respiratory diseases and immunological effects. All the symptoms in Table 2 are associated with OS [Zeliger 2016 , Zeliger 2019 .
Some people suffer higher incidences and increased severities of ADRs than others. Factors that contribute to these enhanced effects include all those listed as OS raising in Table 1 ; age, gender, pregnancy, genetics, drug dose, toxic chemical exposure, polypharmacy, frequency of pharmaceutical drug use, allergy, multimorbidity, chronic inflammation, alcohol use, smoking, body weight and fat distribution, diet and environmental chemical exposures [Alomar, 2014; Lauschke and Ingelman-Sundberg, 2016; Alhawassi, et al., 2014; Gochfeld, 2017; Mendrick, et al., 2017; Kaufmann, et al., 2015; Sushko. et al., 2012; Grzybowski, et al., 2015] . Though it is beyond the scope of this paper to fully explore each of these factors in detail, the following briefly describes each of these and the reader is referred to the cited literature for further discussions.
Age
Older people are more likely to experience ADRs [Alomar, 2014] . There are several reasons for this. As people age, they become more likely to have increasing health problems and thus take increasing numbers of PDs (polypharmacy). With increasing age, the amount of water retained by the body decreases resulting in increases of concentrations of hydrophilic drugs. Since the ratio of fat to muscle tissue increases with age, lipophilic drugs are stored by the body in greater quantities. With aging, liver function declines, lowering the ability of the body to metabolize drugs and the ability of the kidneys to excrete drugs and metabolites into urine also is decreased [Alomar, 2014] .
ADRs are more pronounced in children than in adults due to variabilities in metabolic capabilities and the lack of often inadequate evaluations testing in the young. In this regard, infants are particularly vulnerable [Clavenna and Bonati; .
Gender
Compared to men, women have lower body weight, smaller organ sizes, higher levels of body fat, different gastric motility and varying metabolic and drug elimination rates [Alomar 2014 ]. Women also have increased numbers of acute and chronic health problems than men do [Legato, 1998] . ADR effects are different for pregnant women, as total blood volume increases, resulting in the altering of concentration levels of drugs taken during pregnancy and impacting the pharmacokinetics and pharmacodynamics of the drugs [Duncombe, et al., 2008] 3. Multi-Morbidity ADR prevalence increases with the number of concomitant diseases one ails from [Alomar, 2014] due to the introduction of additional OS elevating factors and the possibilities of drug interactions.
Pharmaceutical Drug Use & Polypharmacy
All PDs cause ADRs and elevate OS. Accordingly, elevated drug dose, greater frequency of drug use and increased number of drugs regularly used (polypharmacy) all elevate OS, [Zeliger, 2016 and the references contained therein].The liver and kidneys are responsible for metabolism and elimination of toxins. The constant insult by daily drug intake challenges the abilities of these organs to effectively function. Also, ADRs to PDs used frequently lead to additional drug use to counteract those ADRs. PDs administered regularly to treat chronic diseases or to lower disease symptoms are prescribed to produce steady state body levels of these drugs, thus maintaining elevated OS levels.
Toxic chemical exposure
Environmental exposures to toxic chemicals have been shown to cause diseases of all body systems and organs, including all diseases associated with ADRs [Grzybowski et al., 2015; Sushko, et al., 2012] . For example, exogenous lipophilic chemical exposures are associated with metabolic, cardiovascular and neurological disease onset in dose response relationships. [Grova, et al., 2019; Lind, et al., 2019 Lee, et al., 2018 ] and hydrophilic exogenous chemical absorption causes numerous cancers, respiratory and neurological diseases [Yegambaram, et al., 2015; Fisseler-Eckhoff, et al., 2011; Caffo, et al., 2014] .
These chemicals, which include persistent organic pollutants such as PCBs, chlorinated pesticides, polybrominated biphenyls and dioxins; phthalates; Bisphenol A; heavy metals including lead, mercury, chromium, arsenic, nickel and cadmium; polynuclear aromatic hydrocarbons; benzene, toluene, xylenes and other hydrocarbons; water chlorination by-products; air pollutants; water pollutants; and numerous others, all elevate OS [Zeliger. 2016] .
Mixtures of chemicals have also been shown to induce the onset of numerous diseases, even when the concentrations of the individual components of the mixtures are below their known toxic levels. Such enhanced effects are observed when chemical mixtures contain at least one lipophilic and one hydrophilic component [Zeliger, 2003; Zeliger, 2011] . Some PDs are lipophilic while others are hydrophilic. Almost all, however, contain excipients to facilitate absorption, maintain stability, color coding and other purposes. The combinations of drugs and excipients set up lipophilic/hydrophilic mixtures that can contribute to toxic effects at lower than expected concentrations. Also, the lipophilic and hydrophilic components of toxic mixtures need not be simultaneously absorbed. Lipophilic species are soluble in body fats and can are retained for longer periods of time (up to decades for persistent organic pollutants) than hydrophilic species and not induce toxicity until a hydrophilic species is sequentially absorbed [Zeliger and Lipinski, 2015] . Accordingly, a lipophilic PD can combine with a hydrophilic species from another source when it is absorbed and a hydrophilic PD can combine with a lipophilic chemical present in the body that is not part of the drug formulations. Both such combinations can induce mixture effects.
Radiation
It is well known that ionizing radiation, x-rays and gamma rays, break chemical bonds in the body and form free radicals that elevate OS. Lower energy ultraviolet [Goswami, et al., 2013] and microwave [Megha, et al., 2015] radiation exposures as well as very low energy radiofrequency [Cahill and Elder 1984] and extremely low frequency, electrical power line emitted, electromagnetic waves [Simco and Mattson, 2004 ] also lead to elevated oxidative stress and have been associated with disease.
Chronic Inflammation
Chronic inflammation can be caused by chronic disease, continual exposure to exogenous toxins, lifestyle choices and other OS raising parameters [Zeliger, 2016] . OS induces inflammation and inflammation leads to OS, setting up a vicious cycle of chronic inflammation [Reuter, et al., 2010] . Chronic inflammation increases cancer risk by impacting every step of tumorigenesis from initiation to tumor promotion and ultimately to metastatic progression [Ikemura, et al 2013] .
ADRs are known initiators of inflammation, a few examples of which are cutaneous eruptions [Hoetzenecker, et al., 2016] , drug-induced fever [Vodovar, et al., 2014] and vascular effects [Kroschinsky, et al., 2017] .
Lifestyle Choices
Lifestyle choices including smoking, alcohol use, recreational drug use and diets high in sugar, salt, saturated fats and processed foods all contribute to elevated OS [Zeliger 2016 ] and also affect ADRs [Alomar, 2014; Hukkanen, et al., 2005; de Boer, et al., 2015] .
Excess Body Fat
Excess body fat provides absorption sites for lipophilic PDs. and serves as a storage site for these. Fats also enhance the absorption of lipophilic PDs across cell membranes. Accordingly, the action of lipophilic PDs, as well as the severity of ADRs in people with excess body fat is both enhanced and prolonged thus increasing the severity of ADRs [Alomar, 2014] .
Genetics and epigenetics
Genetic background is an accepted component of the probability of the onset of numerous diseases, including hypertension, diabetes, obesity and neurodegenerative disorders all of which are associated with elevated OS and ADRs [Balmus, et al., 2016] . Susceptibility to OS is also determined by genetic background, either by directly elevating OS, or by undermining the body's antioxidant defense systems leading to increases in OS [Du, et al., 2012; Gunther, et al., 2018] .
Epigenetic effects, those heritable changes that do not involve an altered DNA sequence, have also been shown to be attributable to PDs [Pirmohamed and Park, 2001; Csoka and Szyf 2009; Kacevska et al., 2011; Hou, et al., 2012] . ADRs known to be associated with epigenetic effects include numerous cancers, diabetes, Alzheimer's disease, Parkinson's disease, osteoporosis, obesity, liver damage and teratogenic malformations. All these are known to be associated with elevated OS [Zeliger, 2016] .
C. Oxidative Stress Index (OSI)
All disease is both a cause and a consequence of oxidative stress. Hence, total OS has been identified as an indicator of the likelihood of disease onset and severity, and is directly related to total OS in a dose response relationship, as discussed above. Total OS may be caused by a combination of genetic load, environmental toxic chemical and radiation exposures, lifestyle, psychological stress, disease prevalence and symptoms, medications regularly taken and chronic inflammation [Zeliger, 2016] .
As discussed above, all parameters that are causative of OS are also associated with increased ADRs. It is hypothesized here that the OS status of an individual can be used to predict the likelihood and severity of adverse effects associated with use of PDs via the use of the OSI. The OSI, based upon responses to a detailed questionnaire, addresses all aspects of a person's OS level can not only predict likelihood of disease [Zeliger, 2019] , but also can be used to predict ADR effects.
Determining steady state OS status via the OSI is valuable for both the patient and the clinician so that, if elevated, can be used to dictate disease and ADR prevention and treatment actions that can be taken to maintain health. When applied to ADR consideration, it can suggest alternative treatment protocols for patients with high OSI levels. The OSI offers the opportunity to accomplish this by producing a steady state profile of a person's OS status and by determining one's OSI as function of time, can demonstrate whether recommended treatment is being effective.
To determine one's OSI, the person, or surrogate, simply checks the items on the questionnaire that apply to her or him and the total number of checks equals the OSI. The following scale has been proposed as indicative of the likelihood of new disease onset [Zeliger 2019 ]. The OSI is shown in Table 3 . Check each of the boxes that apply. If you regularly take five prescription drugs, for example, check all of the first 5 items, so that the total number of items checked equals the total number of prescriptions regularly taken. 1 prescription 2 prescriptions 3 prescriptions 4 prescriptions 5 prescriptions 6 prescriptions 7 prescriptions 8 prescriptions 9 prescriptions 10 or more prescriptions Have a heart pacemaker Total Prescription Medicine Checks ____ DIET:
Check each item that applies to the foods that are part of your regular eat.
Alcoholic beverages (beer, wine, spirits) more than 1 drink per day Artificial sweeteners for coffee or tea Canned or frozen cooked foods regularly eaten (soups, pastas, meats) Bread and pasta made primarily from white processed flour _ Fast food frequently eaten Fewer than 3 fruits or vegetables a day Grilled, smoked or blackened meat, chicken or fish Food high in fat (whole milk, cheeses, foods cooked with butter and animal fat) Often eat processed foods (bacon, hot dogs, salami, sausages. deli meats Eat red meat more than 2 times a week Eat foods high in sugar (sweetened drinks and desserts) Salty food Total Diet Checks ____ LIFE STYLE:
These items refer to where you live, the type of work you do and chemicals you may be exposed to. Though the OSI can predict the likelihood of disease onset, it cannot predict which disease will strike. Similarly, which specific ADRs and how severe they will be as a result of the administration of a particular PD cannot be predicted. The OSI can only demonstrate that there is a likelihood that ADRs will ensue and that their severities will be increased in those with high OSIs. Given that ADRs are concurrent with OS, ADR probability likelihoods will mirror those for disease onset.
The items in the OSI questionnaire are listed alphabetically, rather than by connections to specific parameters, in the different sections so that the responder is challenged to consider each item alone, rather than as part of a series, to which he/she could just check all or eliminate all from consideration.
IV. LIMITATIONS
As with any hypothesis paper, clinical studies are required to confirm what is proposed. Such studies are currently in their preliminary stages.
V. CONCLUSION
ADRs are common when PDs are administered, as drugs are taken regularly to create steady state levels in the body. PDs can be lipophiles and facilitate the absorption of exogenous hydrophiles, or hydrophiles, whose toxicity is enhanced by presence of chemical lipophiles from other sources. ADRs associated with PDs, however, are hypothesized to be related not only to drug active ingredients and excipients, but also to all other endogenous and exogenous sources of OS elevating factors present. It is total OS, which can be easily measured via the OSI, that is responsible for the type, number and severity of resultant ADRs.
Predicting which ADRs will ensue from a particular PD use is extremely difficult, given the numbers and concentrations of endogenous and exogenous chemical species present in a person's body and the numerous mixtures that can arise from combinations of these. Associations of specific ADRs to particular PDs can, at this time, only be made through empirical observations due to the large numbers of OS elevating mixtures potentially present in the body at any given time.
The OSI can be used to demonstrate one's level of OS and suggest lifestyle changes that can be adopted to reduce OS and thus the numbers and severities of ADRs. It is anticipated that treating clinicians will be able to use OSI data to counsel patients when prescribing pharmaceutical drugs to lessen their OS levels and hence their ADRs.
